Leo from United Kingdom

Registered at the short selling broker eToro, 4 minutes ago.

» Try eToro you too
67% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

AbbVie, Inc. (ABBV) shares information

Abbvie Inc


24h Change

0.45 %

ABBV

Live rate: Market closed

Stock data per Tuesday 28 Mar, 2023

ABBV
NEW YORK STOCK EXCHANGE INC.
157.54
157.9
158.25
0.71 (+ 0.45%)
US Market is closed

Live Stock price in graph for Abbvie Inc (ABBV)

  • Latest Volume

    3,532,488 (-9.14 %)

  • Volume prev. day

    3,887,844

  • Avg. daily volume

    7,252,141

  • Market cap

    279,175,437,793

  • P/E ratio

    23.87

  • Today high

    158.599 USD

  • Today low

    157.45 USD

  • 52 week high

    169.46 USD

  • 52 week low

    131.49 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Abbvie Inc

Below you can find the most recent news posts about Abbvie Inc, primarily from US and UK based news sources.

CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies

Tuesday, 28 March 2023, 17:39:52
CytomX Therapeutics (CTMX) stock fell ~15% on Tuesday after FY22 results missed estimates and the company said that AbbVie (ABBV) will not advance cancer drug CX-2029 into…
— Seeking Alpha


AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

Tuesday, 28 March 2023, 17:35:14
CytomX Therapeutics Inc (NASDAQ: CTMX ) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV ) decided not to advance the drug into additional studies . CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement. AbbVie paid $30 million upfront in 2016 to ink the deal and another $15 million in milestones in 2017 for the start of toxicology … Full story available on Benzinga.com
— Benzinga


Who Are Pfizer”s (PFE) Main Competitors?

Saturday, 25 March 2023, 18:38:05
Pfizer”s biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.
— Investopedia


Better Buy: AbbVie vs. Johnson & Johnson

Saturday, 25 March 2023, 10:30:00
These pharma giants beat the bear market last year.
— The Motley Fool


Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen”s Respective IL-23 Entries, According to Spherix Global Insights

Saturday, 25 March 2023, 00:00:00

— Kwhen Finance


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have ABBV available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.